Researchers from the Butantan Institute and collaborators reveal why recombinant BCG induces a stronger and longer-lasting response than the conventional vaccine. Credit: Karina Toledo Researchers from the Butantan Institute and collaborators are developing a more potent version of the BCG vaccine that protects against tuberculosis. While the conventional immunizer reduced infection by 90% in experiments with mice, the so-called recombinant BCG increased the protection rate to 99%. In addition, the new formulation protected the animals for a significantly longer period of time. “BCG is the first vaccine we receive at Read More